ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,701.70
0.96%
S&P ASX All Technology
3,075.00
0.84%
Brent Oil
81.295
0.00%
US Dollar vs AUD
1.49858
-0.15%
Bitcoin
67,749.07
0.40%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Prime Medicine Inc (PRME)

  7. Prime Medicine Inc (PRME) News

PRME

Prime Medicine (PRME)

Prime Medicine Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PRME
DateTimeSourceHeadlineSymbolCompany
30/05/202422:00GlobeNewswire Inc.Prime Medicine to Present at Upcoming Investor ConferencesNASDAQ:PRMEPrime Medicine Inc
22/05/202406:06Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:PRMEPrime Medicine Inc
22/05/202406:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRMEPrime Medicine Inc
13/05/202422:00GlobeNewswire Inc.Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQNASDAQ:PRMEPrime Medicine Inc
10/05/202422:22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRMEPrime Medicine Inc
10/05/202422:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRMEPrime Medicine Inc
10/05/202422:00GlobeNewswire Inc.Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:PRMEPrime Medicine Inc
08/05/202422:00GlobeNewswire Inc.Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)NASDAQ:PRMEPrime Medicine Inc
01/05/202422:00GlobeNewswire Inc.Prime Medicine to Participate in the 27th Annual Milken Institute Global ConferenceNASDAQ:PRMEPrime Medicine Inc
29/04/202421:00GlobeNewswire Inc.Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)NASDAQ:PRMEPrime Medicine Inc
23/04/202422:00GlobeNewswire Inc.Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific MeetingsNASDAQ:PRMEPrime Medicine Inc
02/03/202400:09Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PRMEPrime Medicine Inc
02/03/202400:04Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PRMEPrime Medicine Inc
02/03/202400:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRMEPrime Medicine Inc
02/03/202400:00GlobeNewswire Inc.Prime Medicine Reports Full Year 2023 Financial Results and Provides Business UpdatesNASDAQ:PRMEPrime Medicine Inc
29/02/202400:00GlobeNewswire Inc.Prime Medicine to Participate in Upcoming Investor ConferencesNASDAQ:PRMEPrime Medicine Inc
24/02/202409:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRMEPrime Medicine Inc
24/02/202409:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRMEPrime Medicine Inc
23/02/202413:31Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:PRMEPrime Medicine Inc
21/02/202409:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRMEPrime Medicine Inc
21/02/202408:01GlobeNewswire Inc.Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesNASDAQ:PRMEPrime Medicine Inc
16/02/202422:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRMEPrime Medicine Inc
16/02/202422:17Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PRMEPrime Medicine Inc
15/02/202415:50GlobeNewswire Inc.Prime Medicine Announces Pricing of Upsized Public OfferingNASDAQ:PRMEPrime Medicine Inc
15/02/202413:57Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:PRMEPrime Medicine Inc
15/02/202409:27Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PRMEPrime Medicine Inc
15/02/202408:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRMEPrime Medicine Inc
15/02/202408:05GlobeNewswire Inc.Prime Medicine Announces Proposed Public Offering of Common StockNASDAQ:PRMEPrime Medicine Inc
26/01/202400:00GlobeNewswire Inc.Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic FibrosisNASDAQ:PRMEPrime Medicine Inc
09/01/202400:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRMEPrime Medicine Inc
 Showing the most relevant articles for your search:NASDAQ:PRME

Your Recent History

NASDAQ
RCON
Recon Technology
LSE
13SF
Investec Bnk 28
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved